<?xml version="1.0" encoding="UTF-8"?>
<ref id="B116">
 <label>116.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ishibashi</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Arai</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Yokote</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Araki</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Suganami</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Yamashita</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial</article-title>. 
  <source>J Clin Lipidol</source>. (
  <year>2018</year>) 
  <volume>12</volume>:
  <fpage>173</fpage>â€“
  <lpage>84</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.jacl.2017.10.006</pub-id>
  <?supplied-pmid 29203092?>
  <pub-id pub-id-type="pmid">29203092</pub-id>
 </mixed-citation>
</ref>
